Operating income at Novartis declined by 17% in the first quarter to $2.8 billion as the company was affected by less profitable outcomes for its generics, consumer health and vaccines and diagnostics businesses. Pharmaceutical income was flat. ---Subscribe to MedNous to access this article--- Company News
